Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Objective: To evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH). Patients and methods: With a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diaa-Eldin Taha, Omar M. Aboumarzouk, Ahmed A. Shokeir
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2018
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/1540ee34900a417b978bb272606e3760
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1540ee34900a417b978bb272606e3760
record_format	dspace
spelling	oai:doaj.org-article:1540ee34900a417b978bb272606e37602021-12-02T12:36:26ZOral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature2090-598X10.1016/j.aju.2018.06.007https://doaj.org/article/1540ee34900a417b978bb272606e37602018-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2090598X18300688https://doaj.org/toc/2090-598XObjective: To evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH). Patients and methods: With a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the Cochrane systematic reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Results: The literature search yielded 18 studies. The studies were published between 1980 and 2017, and included 3072 patients. Eligible patients were men aged ≥50 years with lower urinary tract symptoms (LUTS) and persistent nocturia. There was a significant 43% reduction in nocturia after using desmopressin alone. Combined α-blockers and desmopressin lead to a decrease in the frequency of night voids by 64.3% compared to 44.6% when using α-blockers only. The first sleep period, significantly increased from 82.1 to 160.0 min and from 83.2 to 123.8 min when using desmopressin + α-blocker and α-blocker only, respectively. The desmopressin dose ranged from the lowest dose (0.05 mg) to the optimum dose (0.4 mg) at bed time. The incidence of hyponatraemia associated with desmopressin use was 4.4–5.7%. Conclusion: Low-dose oral desmopressin therapy alone is an effective treatment for nocturia associated with LUTS in patients with BPH. Oral desmopressin combined with α-blockers is well tolerated and beneficial for improving the International Prostate Symptom Score and nocturnal symptoms. All patients should be educated about the mechanism of desmopressin action to avoid treatment discontinuation due to adverse events. Keywords: Nocturia, Nocturnal polyuria, Oral desmopressin, LUTSDiaa-Eldin TahaOmar M. AboumarzoukAhmed A. ShokeirTaylor & Francis GrouparticleDiseases of the genitourinary system. UrologyRC870-923ENArab Journal of Urology, Vol 16, Iss 4, Pp 404-410 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Diaa-Eldin Taha Omar M. Aboumarzouk Ahmed A. Shokeir Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
description	Objective: To evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH). Patients and methods: With a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the Cochrane systematic reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Results: The literature search yielded 18 studies. The studies were published between 1980 and 2017, and included 3072 patients. Eligible patients were men aged ≥50 years with lower urinary tract symptoms (LUTS) and persistent nocturia. There was a significant 43% reduction in nocturia after using desmopressin alone. Combined α-blockers and desmopressin lead to a decrease in the frequency of night voids by 64.3% compared to 44.6% when using α-blockers only. The first sleep period, significantly increased from 82.1 to 160.0 min and from 83.2 to 123.8 min when using desmopressin + α-blocker and α-blocker only, respectively. The desmopressin dose ranged from the lowest dose (0.05 mg) to the optimum dose (0.4 mg) at bed time. The incidence of hyponatraemia associated with desmopressin use was 4.4–5.7%. Conclusion: Low-dose oral desmopressin therapy alone is an effective treatment for nocturia associated with LUTS in patients with BPH. Oral desmopressin combined with α-blockers is well tolerated and beneficial for improving the International Prostate Symptom Score and nocturnal symptoms. All patients should be educated about the mechanism of desmopressin action to avoid treatment discontinuation due to adverse events. Keywords: Nocturia, Nocturnal polyuria, Oral desmopressin, LUTS
format	article
author	Diaa-Eldin Taha Omar M. Aboumarzouk Ahmed A. Shokeir
author_facet	Diaa-Eldin Taha Omar M. Aboumarzouk Ahmed A. Shokeir
author_sort	Diaa-Eldin Taha
title	Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
title_short	Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
title_full	Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
title_fullStr	Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
title_full_unstemmed	Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature
title_sort	oral desmopressin in nocturia with benign prostatic hyperplasia: a systematic review of the literature
publisher	Taylor & Francis Group
publishDate	2018
url	https://doaj.org/article/1540ee34900a417b978bb272606e3760
work_keys_str_mv	AT diaaeldintaha oraldesmopressininnocturiawithbenignprostatichyperplasiaasystematicreviewoftheliterature AT omarmaboumarzouk oraldesmopressininnocturiawithbenignprostatichyperplasiaasystematicreviewoftheliterature AT ahmedashokeir oraldesmopressininnocturiawithbenignprostatichyperplasiaasystematicreviewoftheliterature
_version_	1718393784925945856

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Ejemplares similares